Riboxin - instructions for use, dose, side effects, contraindications

Excipients: sucrose (powdered sugar) 0.077 mg, potato starch 61.237 mg, low molecular weight polyvinylpyrrolidone 6.652 mg, stearic acid 2.034 mg, Opadrai II* (series 85) 5,000 mg.

*Composition Opadar II series 85, code 85F32554: polyvinyl alcohol, partially hydrolyzed 40,000%, macrogol 3350 (polyethylene glycol) 20,200%, talc 14,800%, coloring pigment ** 25,000%.

**The composition of the color pigment (yellow): titanium dioxide, E 171 22.320%, aluminum lacquer based on quinoline yellow, E 104 2.430%, iron oxide yellow, E 172 0.250%.

Description:

Round, biconvex tablets, covered with a film membrane of yellow color, two layers are visible on a cross-section; the core of white color.

Pharmacotherapeutic group:metabolic

ATX: & nbsp

C.01.E.B Other drugs for the treatment of heart disease

Pharmacodynamics:

Riboxin belongs to the group of drugs that regulate metabolic processes. Purine derivative (nucleoside), the precursor of adenosine triphosphate (ATP). Has antihypoxic, metabolic and antiarrhythmic effect. Increases the energy balance of the myocardium, improves coronary circulation, prevents the consequences of intraoperative kidney ischemia.It takes a direct part in the exchange of glucose and promotes the activation of metabolism under conditions of hypoxia and in the absence of ATP. Activates the metabolism of pyruvic acid for (ensuring the normal process of tissue respiration, and also promotes the activation of xanthine dehydrogenase.) Stimulates the synthesis of nucleotides, enhances the activity of certain enzymes of the Krebs cycle, penetrates into cells, increases energy metabolism, has a positive effect on the processes of metabolism in the myocardium - and promotes more complete relaxation of the myocardium in diastole, as a result of which the shock volume of blood increases. itov, activates the regeneration of tissues (especially the myocardium and the mucous membrane of the gastrointestinal tract).

Pharmacokinetics:

It is well absorbed in the gastrointestinal tract. Metabolised in the liver with the formation of glucuronic acid and its subsequent oxidation. In a small amount is excreted by the kidneys.

Indications:

Complex therapy of coronary heart disease, myocardial dystrophy, myocardial infarction, heart rhythm disorders due to the use of cardiac glycosides.

Diseases of the liver (hepatitis, cirrhosis, fatty degeneration (against alcoholism or the administration of hepatotoxic drugs)), urocoppororphyria.

Contraindications:

Hypersensitivity to the components of the drug, gout, hyperuricemia, age to 18 years.

Carefully:

Renal failure.

Pregnancy and lactation:

The use of the drug during pregnancy is contraindicated; For the duration of treatment, stop breastfeeding.

Dosing and Administration:

Riboxin is prescribed inside before meals.

The daily dose of the drug for oral administration is 0.6-2.4 g. In the first days of treatment, the daily dose is 0.6-0.8 g (0.2 g 3-4 times a day). If the drug is well tolerated, the daily dose is increased (2-3 days) to 1.2 g (0.4 g 3 times a day), if necessary - up to 2.4 g per day.

Duration of the course - from 4 weeks to 1,5-3 months.

With urocoppororphy, the daily dose is 0.8 g (0.2 g 4 times a day).

The drug is taken daily for 1-3 months.

Side effects:

Allergic reactions in the form of urticaria, skin itching, skin hyperemia (the drug is canceled).

Rarely, Riboxin treatment increases the concentration of uric acid in the blood, possibly exacerbation of gout (with prolonged use).

Overdose:

In the presence of the phenomena of individual intolerance, the drug is canceled and desensitizing therapy is performed.

It is possible to increase the level of uric acid in the blood, which in patients with gout leads to an aggravation, requiring the drug to be withdrawn.

Interaction:

When used as part of complex therapy, Riboxin helps to increase the effectiveness of antiarrhythmic, antianginal and inotropic drugs.

Clinically significant interaction of Riboxin with drugs of other groups is not described.

Special instructions:

Particular caution in the appointment of Riboxin should be observed in patients with impaired renal function. It is recommended to control the level of uric acid and urea in the blood.

Use in Pediatrics: Riboxin in the form of tablets can be used according to indications in children over the age of 3 years.

Use in leukopenia: the use of Riboxin is not recommended in severe forms of leukopenia, with a level of neutrophils of peripheral blood below 1.5 × 10⁹ in a liter.

Effect on the ability to drive transp. cf. and fur:

Receiving Riboxin does not affect the ability of the patient to drive a vehicle or other operator activities.

Form release / dosage:

Tablets, film-coated, 200 mg.

Packaging:

For 10 tablets in a planar cell package.

For 5 contour packs together with instructions for use in a pack of cardboard.

Storage conditions:

In a dry, protected from light place, at a temperature of no higher than 25 ° C.

Keep out of the reach of children.

Shelf life:

3 years.

Do not use after the expiration date printed on the package.

Terms of leave from pharmacies:On prescription

Registration number:П N015362 / 02

Date of registration:06.11.2009

The owner of the registration certificate:BORISOVSKIY FACTORY OF MEDPREPARATES, OJSC BORISOVSKIY FACTORY OF MEDPREPARATES, OJSC Republic of Belarus

Manufacturer: & nbsp

BORISOVSKIY FACTORY OF MEDPREPARATES, OJSC Republic of Belarus

Representation: & nbspBORISOVSKIY FACTORY OF MEDPREPARATES, OJSCBORISOVSKIY FACTORY OF MEDPREPARATES, OJSC

Information update date: & nbsp22.10.2015

Illustrated instructions

Instructions

Riboxin (Riboxin)